Immunocore Holdings (IMCR) Amortization of Deferred Charges (2023 - 2026)

Immunocore Holdings (IMCR) has reported Amortization of Deferred Charges for 4 consecutive years, with $627000.0 the latest figure, recorded in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 14.84% year-over-year to $627000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 19.89% YoY) and the FY2025 annual result came in at $2.3 million, up 22.8% from the prior year.
• Amortization of Deferred Charges eased to $627000.0 in Q1 2026 per IMCR's latest filing, from $667000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for IMCR reached as high as $667000.0 in Q4 2025 and fell as low as $401000.0 in Q2 2023.
• A 4-year average of $502615.4 and a median of $488000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2024 — Amortization of Deferred Charges rose 6.14% — and 2025, when it jumped 31.48%.
• Year by year, Amortization of Deferred Charges stood at $437000.0 in 2023, then climbed by 28.15% to $560000.0 in 2024, then increased by 19.11% to $667000.0 in 2025, then dropped by 6.0% to $627000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $627000.0, $667000.0, and $567000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.